Antifungal Agents Recently Approved or Under Development, 2nd Edition
A special issue of Journal of Fungi (ISSN 2309-608X). This special issue belongs to the section "Fungal Pathogenesis and Disease Control".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 48
Special Issue Editor
Interests: antifungal susceptibility testing and development of ECVs for fungal species; antifungal resistance; medical mycology; epidemiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Since the previous edition of this Special Issue, numerous clinical trials have been conducted on several agents for combating the following fungal infections: Three studies evaluated the efficacy and safety of osteseconazole (one study against fluconazole) in the treatment of recurrent vulvovaginal candidiasis. Four studies investigated ibrexafungerp for the treatment of vulvovaginal candidiasis, including one study of the efficacy and safety of oral ibrexafungerp (SCY-078), as well as a phase III CANDLE study on the prevention of recurrent vaginal yeast infections.
The literature reports two studies of the efficacy and safety of oral ibrexafungerp for patients with invasive candidiasis or candidaemia caused by Candida auris. A phase III randomized double-blind study was reported for patients with invasive candidiasis treated with IV echinocandin followed by ibrexafungerp or oral fluconazole. Four studies reported rezafungin-versus-caspofungin data for the treatment of candidaemia and/or invasive candidiasis, including one study that examined the efficacy and safety of the two agents.
Another study investigated oral lipid nanocrystal amphotericin B for the treatment of cryptococcal meningitis.
We found several clinical studies of filamentous fungi. Four studies with olorofim (F901318) reported the following: in vitro activity against difficult-to-treat aspergillus isolates, scedpsporium and Lomentospora prolificans isolates, the molecular mechanisms of acquired olorofim resistance, and the treatment of invasive mold infections in patients with limited or no treatment options.
Finally, two studies investigated opelconazole (PC945) activity in combination with other antifungal therapies for the treatment of refractory invasive pulmonary aspergillosis as well as the in vitro and in vivo antifungal activity of inhaled olorofim.
Any other data that should be reported for the filamentous fungi with the new agents will be appreciated.
Dr. Ana V. Espinel-Ingroff
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antifungal agents
- osteseconazole
- ibrexafungerp
- olorofim
- opelconazole
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
